Therapy
Nivolumab
Monoclonal antibody targeting PD-1.
Also called: nivolumab, Opdivo, NIVO
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 3 and is affected by 1 concepts — mostly 1 cell, 1 receptor, 2 trial.
- 3Where it sits: therapy on the 15-step immune chain.
What it does
Fully human IgG4κ (stabilised); anti-PD-1; approved: melanoma, NSCLC, SCLC, RCC, HCC, CRC (MSI-H), HNSCC, gastric, esophageal; nivo+ipi (CheckMate-067): melanoma 5yr OS 52%; CheckMate-8HW: nivo+ipi vs chemo in MSI-H mCRC → PFS HR 0.21
Its connections at a glance
Each dot is a concept directly linked to Nivolumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I009 · concept status: established. Select any connection above to inspect evidence for that specific link.